Management reaffirmed full-year continuing operations revenue guidance of $165.0 million to $172.0 million, implying organic growth of 5%–10%. No updated profit forecast was provided, though executives have previously outlined a path to positive adjusted EBITDA within the year. Investors should monitor expansion in high-margin commercial therapy services, the pace of new cryogenic product rollouts and the trend in supported commercial therapies as a leading demand indicator. The deployment of significant cash reserves toward research and development, acquisitions or additional buybacks will also be critical to sustaining momentum. Following the divestiture of the CRYOPDP courier business—which generated a one-time after-tax gain of $117.4 million—Cash, cash equivalents and short-term investments rose to $426.0 million as of June 30, 2025. The board authorized a share repurchase program with 1.0 million shares acquired at an average cost of $6.76 for 628,217 shares during the quarter and $7.36 for 371,783 shares post-quarter, leaving $66.9 million available for buybacks. Management indicated that capital allocation will prioritize strategic technology investments, potential acquisitions and further share repurchases. Cryoport delivered GAAP revenue of $45.5 million in Q2 fiscal 2025, representing a 14.5% increase over the year-ago quarter and beating consensus estimates by roughly $3.8 million. Gross margin from continuing operations expanded by 2.5 percentage points to 47.0%, driven by operational efficiencies in both services and products. The adjusted EBITDA loss narrowed substantially to $0.9 million, compared with a $5.6 million loss in Q2 2024, signaling material progress on the path toward profitability despite the ongoing unprofitable status at the operating line. Life Sciences Services revenue rose 20.9% year-over-year to $24.4 million, with BioStorage and BioServices increasing 28% and BioLogistics Solutions up 20%. Life Sciences Products revenue accounted for 46% of total sales at $21.1 million, up 8% year-over-year, powered by heightened demand from animal health customers. Commercial cell and gene therapy logistics grew 33% to $8.7 million, while the number of supported commercial therapies stood at 18 as of quarter-end. Clinical trial support increased by 44 trials to 728, underscoring robust engagement in early-stage programs.
Management reaffirmed full-year continuing operations revenue guidance of $165.0 million to $172.0 million, implying organic growth of 5%–10%. No updated profit forecast was provided, though executives have previously outlined a path to positive adjusted EBITDA within the year. Investors should monitor expansion in high-margin commercial therapy services, the pace of new cryogenic product rollouts and the trend in supported commercial therapies as a leading demand indicator. The deployment of significant cash reserves toward research and development, acquisitions or additional buybacks will also be critical to sustaining momentum. Following the divestiture of the CRYOPDP courier business—which generated a one-time after-tax gain of $117.4 million—Cash, cash equivalents and short-term investments rose to $426.0 million as of June 30, 2025. The board authorized a share repurchase program with 1.0 million shares acquired at an average cost of $6.76 for 628,217 shares during the quarter and $7.36 for 371,783 shares post-quarter, leaving $66.9 million available for buybacks. Management indicated that capital allocation will prioritize strategic technology investments, potential acquisitions and further share repurchases. Cryoport delivered GAAP revenue of $45.5 million in Q2 fiscal 2025, representing a 14.5% increase over the year-ago quarter and beating consensus estimates by roughly $3.8 million. Gross margin from continuing operations expanded by 2.5 percentage points to 47.0%, driven by operational efficiencies in both services and products. The adjusted EBITDA loss narrowed substantially to $0.9 million, compared with a $5.6 million loss in Q2 2024, signaling material progress on the path toward profitability despite the ongoing unprofitable status at the operating line. Life Sciences Services revenue rose 20.9% year-over-year to $24.4 million, with BioStorage and BioServices increasing 28% and BioLogistics Solutions up 20%. Life Sciences Products revenue accounted for 46% of total sales at $21.1 million, up 8% year-over-year, powered by heightened demand from animal health customers. Commercial cell and gene therapy logistics grew 33% to $8.7 million, while the number of supported commercial therapies stood at 18 as of quarter-end. Clinical trial support increased by 44 trials to 728, underscoring robust engagement in early-stage programs.